Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Linear Ubiquitin Chain Assembly Complex (LUBAC) is a multi-subunit E3 ubiquitin ligase composed of HOIP (RNF31), HOIL-1L (RBCK1), and SHARPIN [1]. It is uniquely characterized by its ability to catalyze the formation of M1-linked (linear) ubiquitin chains, which are critical regulators of the canonical NF-kappaB signaling pathway [2]. By attaching linear ubiquitin chains to substrates such as NEMO (IKK-gamma), LUBAC facilitates the recruitment and activation of the IKK complex, leading to the transcription of genes involved in inflammation, immune response, and cell survival [3]. Dysregulation of LUBAC is implicated in several pathologies, including activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), where it promotes oncogenic signaling, and various autoinflammatory and immunodeficiency syndromes [4, 5]. Because of its central role in pro-survival signaling, LUBAC is an attractive therapeutic target for cancer and chronic inflammatory diseases [6]. Small-molecule inhibitors, such as HOIPINs, are currently being developed to selectively block the catalytic activity of the HOIP subunit to dampen pathological NF-kappaB activation [7]. Sources: [1] Kirisako et al. (2006) EMBO J; [2] Tokunaga et al. (2009) Nature; [3] Gerlach et al. (2011) Nature; [4] Yang et al. (2014) Cancer Cell; [5] Boisson et al. (2012) J Exp Med; [6] Kloetgen et al. (2020) Commun Biol; [7] Katsuya et al. (2018) Biochem J.
Inhibition of the HOIP subunit's catalytic RBR domain to prevent the assembly of M1-linked ubiquitin chains, thereby blocking the activation of the IKK complex and downstream NF-kappaB signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Linear Ubiquitin Chain Assembly Complex (LUBAC) (LUBAC).